Catalyst Pharmaceuticals Inc (CPRX) Given Consensus Recommendation of “Buy” by Brokerages

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has been assigned an average rating of “Buy” from the nine analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $6.00.

CPRX has been the subject of several research reports. BidaskClub cut Catalyst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 8th. HC Wainwright set a $6.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 22nd. Zacks Investment Research raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 target price for the company in a research note on Monday, August 13th. Oppenheimer set a $6.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, October 16th. Finally, Cantor Fitzgerald set a $8.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Friday.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CPRX. Schwab Charles Investment Management Inc. increased its stake in shares of Catalyst Pharmaceuticals by 24.3% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 184,904 shares of the biopharmaceutical company’s stock valued at $442,000 after buying an additional 36,200 shares during the period. Northern Trust Corp increased its stake in shares of Catalyst Pharmaceuticals by 22.5% in the 1st quarter. Northern Trust Corp now owns 1,009,947 shares of the biopharmaceutical company’s stock valued at $2,414,000 after buying an additional 185,639 shares during the period. BlackRock Inc. increased its stake in shares of Catalyst Pharmaceuticals by 16.9% in the 1st quarter. BlackRock Inc. now owns 4,698,531 shares of the biopharmaceutical company’s stock valued at $11,230,000 after buying an additional 678,950 shares during the period. New York State Common Retirement Fund increased its stake in shares of Catalyst Pharmaceuticals by 47.6% in the 1st quarter. New York State Common Retirement Fund now owns 74,994 shares of the biopharmaceutical company’s stock valued at $179,000 after buying an additional 24,200 shares during the period. Finally, GSA Capital Partners LLP acquired a new stake in shares of Catalyst Pharmaceuticals in the 1st quarter valued at $230,000. 51.49% of the stock is owned by institutional investors.



CPRX stock opened at $3.12 on Friday. Catalyst Pharmaceuticals has a fifty-two week low of $2.18 and a fifty-two week high of $4.51. The firm has a market cap of $326.27 million, a P/E ratio of -14.86 and a beta of 1.46.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings results on Friday, August 10th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.02. Equities analysts anticipate that Catalyst Pharmaceuticals will post -0.29 earnings per share for the current fiscal year.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Further Reading: Fundamental Analysis

Analyst Recommendations for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply